Connect Biopharma to Host Conference Call on January 5 at 8:30 AM ET to Review Detailed Data from the Global Phase 2b Trial of CBP-201
Connect Biopharma Holdings Limited (Nasdaq: CNTB) will host a conference call and webcast on January 5, 2022, at 8:30 AM Eastern Time to discuss detailed data from its Phase 2b trial of CBP-201 for moderate-to-severe atopic dermatitis. The trial aims to evaluate the safety and efficacy of CBP-201, an antibody targeting IL-4Rα. This call is a significant step for Connect Biopharma as they continue to advance their pipeline of therapies for chronic inflammatory diseases. Interested parties can access the call via a provided link or by phone.
- Scheduled conference call on January 5, 2022, to present data from Phase 2b trial of CBP-201.
- Focus on chronic inflammatory diseases positions company for potential market impact.
- None.
SAN DIEGO and TAICANG, China, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it will host a conference call and webcast to review detailed data from its global Phase 2b trial of CBP-201 in adult patients with moderate-to-severe atopic dermatitis on Wednesday, January 5, 2022 beginning at 8:30 AM Eastern Time.
The conference call can be accessed using the following information:
Webcast: https://edge.media-server.com/mmc/p/2pa7xiwr
U.S.: 844-646-2698
Outside of U.S.: 918-922-6903
Conference ID: 7998162
The webcast will be available in the “Investors” section of the Company’s website following the completion of the call.
About Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from our T cell-driven research.
Our lead product candidate, CBP-201 — an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) — has been in clinical trials for the treatment of atopic dermatitis (AD), asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP). Our second lead product candidate, CBP-307 — a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1 (S1P1) — has been in clinical trials for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD). Furthermore, we have started the clinical development of an additional product candidate, CBP-174 — a peripherally acting antagonist of histamine receptor 3 — for the treatment of pruritus associated with AD.
With clinical development activities in the United States, China, Europe, and Australia, and operations in those geographies as well as Hong Kong, Connect Biopharma is building a rich global pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology. For additional information about Connect Biopharma, please visit our website at www.connectbiopharm.com.
IR/PR CONTACTS:
Lazar FINN Partners
David Carey (IR)
T: +1-(212) 867-1768
david.carey@finnpartners.com
Erich Sandoval (Media)
T: +1-(917) 497-2867
erich.sandoval@finnpartners.com
Corporate Contacts:
info@connectpharm.com
FAQ
What is the purpose of the Phase 2b trial for CBP-201?
When is the conference call for the CBP-201 trial results?
How can I access the Connect Biopharma conference call?
What diseases is CBP-201 being tested for?
What is the significance of CBP-201 in Connect Biopharma's pipeline?
